奥氮平联合利培酮治疗难治性精神分裂症患者的临床疗效及对TESS评分的影响

Clinical Efficacy of Olanzapine Combined with Risperidone in the Treatment of Refractory Schizophrenia and Its Influence on TESS Score

目的:探讨奥氮平联合利培酮治疗难治性精神分裂症患者的临床效果及对TESS评分的影响。方法:选取2018年6月-2019年10月入住本院的难治性精神分裂症患者54例。应用随机数字表法将患者分为对照组和研究组,每组27例。对照组应用奥氮平进行治疗,研究组应用奥氮平联合利培酮进行治疗。观察两组患者的临床疗效,比较两组的PANSS、TESS评分及患者的治疗依从性。结果:研究组的临床总有效率为92.6%,优于对照组的59.3%,差异有统计学意义(P<0.05)。治疗前,两组患者的阳性症状、阴性症状、一般精神病理症状及总分比较,差异均无统计学意义(P>0.05);治疗4、6、8周后,研究组的阳性症状、阴性症状、一般精神病理症状及总分均明显低于对照组,差异均有统计学意义(P<0.05)。研究组治疗依从性为92.6%,优于对照组的70.4%,差异有统计学意义(P<0.05)。治疗2、4、6、8周后,研究组的TESS评分均低于对照组,差异均有统计学意义(P<0.05)。结论:应用奥氮平联合利培酮对难治性精神分裂症患者实施治疗,患者的阳性及阴性等症状均获得明显的改善,PANSS评分得到极大的降低,患者的治疗依从性更高,TESS评分较低,疗效显著,可以推广应用。

Objective:To investigate the clinical efficacy of Olanzapine combined with Risperidone in the treatment of refractory schizophrenia and the influence of TESS score.Method:A total of 54 patients with refractory schizophrenia admitted to our hospital from June 2018 to October 2019 were selected.They were divided into control group and study group by random number table method,27 cases in each group.The control group was treated with Olanzapine,while the study group was treated with Olanzapine combined with Risperidone.The clinical efficacy of the two groups was observed,and the PANSS,TESS scores and treatment compliance of the two groups were compared.Result:The total clinical effective rate of the study group was 92.6%,which was better than 59.3%of the control group,with statistically significant difference(P<0.05).Before treatment,there were no statistically significant differences in positive and negative symptoms,general psychopathological symptoms and total scores between the two groups(P>0.05).After 4,6 and 8 weeks of treatment,positive and negative symptoms,general psychopathological symptoms and total scores of the study group were significantly lower than those of the control group,the differences were statistically significant(P<0.05).The treatment compliance of the study group was 92.6%,superior to 70.4%of the control group,the difference was statistically significant(P<0.05).After 2,4,6 and 8 weeks of treatment,TESS scores of the study group were lower than those of the control group,the differences were statistically significant(P<0.05).Conclusion:The application of Olanzapine combined with Risperidone in the treatment of refractory schizophrenia has significantly improved the positive and negative symptoms of the patients,greatly reduced PANSS score,higher treatment compliance of the patients,low TESS score,significant therapeutic effect,and can be popularized.